Voyager Therapeutics Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Voyager Therapeutics's estimated revenue is currently $7.6M per year.
- Voyager Therapeutics received $75.0M in venture funding in November 2017.
- Voyager Therapeutics's estimated revenue per employee is $39477
- Voyager Therapeutics's total funding is $205M.
- Voyager Therapeutics has 193 Employees.
- Voyager Therapeutics grew their employee count by 45% last year.
- Voyager Therapeutics currently has 1 job openings.
|Dinah Sah||Chief Scientific Officer|
|Robert Pietrusko||Senior Vice President, Regulatory Affairs & Quality Assurance|
|Xiaobing Li||Vice President, Program Management|
|Steven Hersch||Vice President, Clinical Research and Development|
|Kyle Grant||Associate Director|
|Christopher Morrison||Director - Biopharmaceutical Development|
|Luis Maranga||Chief Technical Operations Officer|
|Rajiv Gangurde||Director, Chemistry, Manufacturing & Controls (CMC)|
|Allan Capili||Director, Antibody Platform|
|Matt Ottmer||Chief Operating Officer|
What Is Voyager Therapeutics?
Voyager Therapeutics is developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of Parkinson's disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, Alzheimer's Disease and other tau-related neurodegenerative diseases, and severe, chronic pain. We are also committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, dosing techniques, as well as process development and production. Our management team and founders represent some of the most esteemed scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference, neuroscience preclinical and clinical development, and manufacturing. We have broad strategic collaborations with Genzyme, a Sanofi company, AbbVie and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California San Francisco and Stanford University to access relevant technology and data. Contact: Voyager Therapeutics 75 Sidney St. Cambridge, MA 02139 email@example.com 857-259-5340keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Voyager Therapeutics News
On Wednesday, shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) marked $16.77 per share versus a previous $17.11 closing price.
DekaBank Deutsche Girozentrale lifted its stake in Voyager Therapeutics Inc (NASDAQ:VYGR) by 63.6% in the 2nd quarter, according to the ...
On Thursday's Current Session, Voyager Therapeutics, Inc. (NASDAQ:VYGR) closing at $17.00 price level during recent trade its distance from ...
Voyager Therapeutics Funding
|2014-02-13||$45.0M||A||Third Rock Ventures||Article|
Voyager Therapeutics Executive Hires
|2014-06-27||Robert G. Pietrusko||SVP Regulatory Affairs||Article|
|2015-04-29||Jeff Goater||VP Finance/Business Development||Article|
|2018-06-29||Andre Turenne||President and Chief Executive Officer||Article|
|2019-01-23||Robert Hesslein||General Counsel||Article|
Voyager Therapeutics New Location/Offices